(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 February 2012 (16.02.2012)

PCT

(10) International Publication Number
WO 2012/021696 A1

(51) International Patent Classification:
A61K 31/33 (2006.01) *A61K 31/425* (2006.01)

(21) International Application Number:
PCT/US2011/047407

(22) International Filing Date:
11 August 2011 (11.08.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/372,594 11 August 2010 (11.08.2010) US
61/438,375 1 February 2011 (01.02.2011) US

(71) Applicant *(for all designated States except US)*: **MILLENNIUM PHARMACEUTICALS, INC.** [US/US]; 40 Landsdowne Street, Cambridge, MA 02139 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **FREEZE, Brian S.** [US/US]; 67 Gates Street, Unit 1, Boston, MA 02127 (US). **HIROSE, Masaaki** [JP/JP]; C/o Takeda Pharmaceutical Company Limited, Oncology DDU, C-1 2F 1110, 26-1, Muraokahigashi 2-chome, Fujisawa, Kanagawa, 251-0012 (JP). **HU, Yongbo** [US/US]; 24 Shepard Court, Winchester, MA 01890 (US). **HU, Zhigen** [CN/US]; 42 Truman Road, Newton Center, MA 02459 (US). **LEE, Hong Myung** [KR/US]; 321 Harvard Street #309, Cambridge, MA 02139 (US). **SELLS, Todd B.** [US/US]; 32 Ray Avenue, Bellingham, MA 02019 (US). **SHI, Zhan** [US/US]; 18 Shagbark Road, Concord, MA 01742 (US). **VYSKOCIL, Stepan** [CZ/US]; 34 Eustis Street, Arlington, MA 02476 (US). **XU, Tianlin** [US/US]; 2 Arrowwood Drive, Shrewsbury, MA 01545 (US).

(74) Agents: **SHAIR, Karoline K. M.** et al.; Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, MA 02139 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) **Title**: HETEROARYLS AND USES THEREOF



(IA-a)



(IB-a)

(57) **Abstract**: This invention provides compounds of formula (IA-a) or (IB-a) and subsets thereof: wherein Z, HY, R^1, R^2, G_1 W, n, and A and subsets thereof are as described in the specification. The compounds are inhibitors of PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

WO 2012/021696 A1